Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
In brief: This is a multicenter, randomized, non-comparative, phase II proof-of-concept trial involved patients with progressive vitiligo and uses one of the most common regimens in this phase of study. Assessment of the experimental treatment efficacy will be estimated only on the results obtained in the experimental treatment arm (baricitinib 4 mg/day + narrowband UVB TL01 arm).
Ages eligible: 18 Years to 75 Years
Start date: May 1, 2021
Completion date (estimated): November 30, 2023
Location: Hôpital Saint-André, Bordeaux, France
Status: Active, recruiting
Contact: To learn more about this study, you or your doctor may contact Dr. Julien SENESCHAL at +33 (0)5 56 79 47 05 or julien.seneschal@chu-bordeaux.fr
Please refer to this study by its ClinicalTrials.gov identifier NCT04822584
FAQOther Questions
- Is vitiligo contagious?
Vitiligo is NOT contagious. It cannot be passed on or caught from touching someone with vitiligo, shaking hands, swimming in the same pool, sharing towels, sitting next to someo...
- What's better: laser or phototherapy?
In a recent study researchers assessed effect and safety of different laser and phototherapy treatments, such as excimer laser/light, narrowband UVB, UVA and PUVA. No significa...
- Does vitiligo increase the risk of skin cancer?
No, it does not. Despite common misconceptions, people with vitiligo are actually at a lower risk of developing skin cancer, including both nonmelanoma skin cancer (NMSC) and ma...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.